Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. - Wikidata - wikimedia - TriplyDB

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q38197831

about

Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis Current systemic treatment of hepatocellular carcinoma: A review of the literature Hepatocellular carcinoma: A comprehensive review Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit.Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis Evolving role of Sorafenib in the management of hepatocellular carcinoma.Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.Management of hepatocellular carcinoma: an overview of major findings from meta-analyses Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy.Systemic treatment for hepatocellular carcinoma: Still unmet expectations Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy.Sorafenib-induced acute-on-chronic liver failure in a patient with hepatocellular carcinoma after transarterial chemoembolization and radiofrequency ablation: A case report.Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trial Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model.Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.Prognostic Impact of Visceral Fat Amount and Branched-Chain Amino Acids (BCAA) in Hepatocellular Carcinoma.Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway.Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review

P2860

Q26740315-DDF46E69-A664-4C64-84FD-B5A07898BF00 Q26749847-0A0DEEF1-0092-426A-93B0-7CD47FA1A7F9 Q27026036-F9D1A7BE-E839-44AD-9973-FEBE4619DE13 Q28087638-07A22773-B511-4BEB-8B9D-16599480E672 Q30845071-AC2C7E12-8768-4EDD-B272-F21BC2114E2C Q33590673-3C01D306-DA89-42C2-BA3A-5852D2CD80B0 Q33665679-6E377BA7-EF8B-4830-A386-18893CA56529 Q33710153-6195ABF8-38A7-42AC-88EF-152A43AB18A1 Q33779864-1AE7EB52-0DE4-4AC9-BAE8-4696EF9588C0 Q35625989-9498C982-D121-4A3A-BF7A-F6333470338D Q35917459-210CD44A-9FCA-463A-95C8-479169E11536 Q36014255-79DED6FC-7FD5-4D0F-96D0-6D5574C6A89B Q36183134-772D04CD-65ED-44C8-98D3-C947B0074D5F Q36210228-484C5324-AAF4-417D-BDC5-FBE3A4FB9893 Q36278698-A7010891-E5BE-4127-BE20-C3152FB73E02 Q36325065-8958BE6F-F247-4B82-ADAB-7CA95072AAE0 Q36344688-DAC023D5-2BD8-4BE8-9537-DEDD1809522C Q36747526-997CB704-8356-4C79-A0DE-26AC88F60A6A Q37114870-E72E7679-AC99-4466-A65D-73697615BA21 Q37696388-A385BA72-FF21-40E0-8F22-C4680E7DC4FD Q38923548-494CFE07-DCC7-49FF-9A04-973474869902 Q39112745-0550B595-B16F-4D30-83A4-8C35C40D965F Q40846805-A75AC9B6-18F7-4483-BE64-E218EB370F5F Q41418212-FB5435DC-AF35-4BC1-BD4D-EB8640B40E82 Q41542341-1E916350-7C94-4B5D-B99A-CF5CC7FB66D8 Q42173132-F3A20BBC-0EF0-4FBB-9A99-3C950C3CAA76 Q42199684-74CC535E-6D59-4206-9ECD-93AF9E2B3C32 Q42362049-1CA91A1A-49D8-4B2B-A241-A5C613D90504 Q48309588-53F28475-848D-45C2-8491-AC6FEB37B969 Q48411584-2AD9F810-4D8C-43C2-93C6-E8EEAEBB9D8A Q48722303-DDB9B70A-DFB2-42EC-B2D6-B8011DE021C3 Q49627939-4CBA0856-ACB3-4EC1-B0CA-0E850A2190F2 Q52584231-83AF9071-A165-4CB7-938E-49F5B46DBF07 Q52686882-953E0B41-3EBD-4AC6-831E-2DDCE6DB0F3C Q53178946-6E080683-F295-4B14-8B3B-6DC3258B9763 Q53214610-1897D499-C7FD-4B00-A632-8BB771D3DA2A Q54118581-A01DFD85-3E4D-4AD1-A736-A6F630898895 Q58755253-66B79D90-4C6D-4911-AAF3-78A7E7451E3E

P2860

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q38197831

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Combination therapy of sorafen ...... atic review and meta-analysis.

@en

type

label

Combination therapy of sorafen ...... atic review and meta-analysis.

@en

prefLabel

Combination therapy of sorafen ...... atic review and meta-analysis.

@en

P1433

Q38197831-9EA641B1-2D28-4DC6-8238-D55D632C3FD4

P1476

Q38197831-07388BE2-7ADC-4580-9DEA-00A539DDE481

P2093

Q38197831-31AB564E-1AE7-4BEF-8852-F56730BD2C94

Q38197831-3FB1FBE4-23DF-4569-87ED-D3DF7F74D40F

Q38197831-5C3AD06E-4C71-4889-AC57-2412A4F957F9

Q38197831-61DF38B4-9C7D-41B5-8639-ABBA50F54E9D

Q38197831-98430497-D5B0-478C-8270-4832E6C9CECE

Q38197831-9CC3E3F9-7597-4BE8-8A1A-317B6AD001B5

Q38197831-F59B86B2-97ED-4EB5-91AC-ECFAF725EB62

P275

Q38197831-8046D90A-A487-4066-8869-25C7EB24AC9B

P2860

Q38197831-0A8821E5-5615-4F98-9EA3-8C4878CFC890

Q38197831-17FCD19E-9B22-47CC-B0FC-24270937FCF2

Q38197831-1B43992F-3C52-4EBE-8AE7-8622FF4A61B7

Q38197831-1DA6395B-75E6-4D73-B963-B24C10D157F9

Q38197831-47984AFC-C2AB-4C9D-BE17-BC9FC7D771DF

Q38197831-4C904AC4-50AD-4913-8C9B-C212358856D3

Q38197831-526C988E-28CA-4EBA-ABC5-D0F614F6C3DD

Q38197831-54D2CD49-AED2-4CD0-918D-F9E2757FF835

Q38197831-55040D14-6C4C-497C-A712-3A605C797F23

Q38197831-5B635C51-024B-463D-8721-885AD6064700

P304

Q38197831-23C3F1FD-32CE-4327-95C3-EC129C176E4B

P31

Q38197831-4A23FDC2-6097-4BCE-8D85-3BA89684AB86

Q38197831-74F00AC1-0151-4DCE-8173-3A8D5FC4B9FC

Q38197831-7b6bc34c-e2fd-4ea7-b56a-c04ea2352dca

P356

Q38197831-E2F32BEB-C50E-43D1-89F2-B44FB73AF09B

P407

Q38197831-D7E33450-4F75-444F-9B37-C312D68AE1FE

P433

Q38197831-6C1D9ED0-4B07-4E1C-9AE8-690841C4A40D

P478

Q38197831-C745A01D-0051-4FB0-956E-5EA34561D9AD

P5008

Q38197831-FF91D5BA-C3F8-4687-9E39-DC9BF1EAD437

P577

Q38197831-E90AFC02-CCE0-43B0-86BC-C1461B16F527

P5875

Q38197831-A1AD9DA1-9FD5-4873-AE53-C65FC274D0C4

P698

Q38197831-C83CF759-9C44-423A-92B2-E3819F6BCF3F

P921

Q38197831-2FF9B58C-322B-42D5-8AF7-A8F326D642E9

Q38197831-A0E26EE7-1333-4BB0-AE81-D97624CE44E2

Q38197831-B0C253D4-32DF-4090-8458-E318B0E56BA2

Q38197831-D1B5FD99-D1A1-48F8-B409-8519E8870EFD

Q38197831-E4FA37A0-22B4-4827-98A5-3AA2590B9E56

P932

Q38197831-83AD02C9-9CD4-42E5-9880-9D6B2D8E16DC

P356

JOURNAL.PONE.0091124

P1433

P1476

Combination therapy of sorafen ...... atic review and meta-analysis.

@en

P2093

Guohong Cai

http://www.w3.org/2001/XMLSchema#string

Guohong Han

http://www.w3.org/2001/XMLSchema#string

Hui Chen

http://www.w3.org/2001/XMLSchema#string

Lei Liu

http://www.w3.org/2001/XMLSchema#string

Mengmeng Wang

http://www.w3.org/2001/XMLSchema#string

Xingshun Qi

http://www.w3.org/2001/XMLSchema#string

Yan Zhao

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Global cancer statistics, 2002

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Management of hepatocellular carcinoma

Hepatocellular carcinoma

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

P304

e91124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0091124

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260996421

http://www.w3.org/2001/XMLSchema#string

P698

24651044

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

P932

3961236

http://www.w3.org/2001/XMLSchema#string